Rewind Therapeutics Funding Round

1/25/2023

Unknown

Undisclosed

The proceeds will be used to advance Rewind Therapeutics´ lead program into clinical development and further broaden the Company´s pipeline of drug candidates designed to restore the remyelination function of the central nervous system (CNS). Myelin forms a protective layer around neurons and is essential for their proper functioning. Neurodegenerative disorders such as multiple sclerosis are associated with a damaged, deteriorating myelin sheath, which ultimately leads to a range of symptoms such as depression, anxiety, irritability, and even death due to a breakdown of the vital neurological functions.

Private & Independent

Biopharmaceutical

Gaston Geenslaan 2
Leuven, 3001
Belgium

Undisclosed

Rewind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. A common feature of these illnesses is the loss of the natural myelin sheath, a cover protecting and nurturing the nerves. Repairing or re-installing this sheath (i.e., remyelination) is a crucial factor for halting or even curing these diseases. Rewind´s team has extensive research and development expertise and a strong patent estate for developing novel remyelination therapeutics. Based in Leuven, Belgium, Rewind is backed by top-tier life science investors such as Boehringer Ingelheim Venture Fund, M. Ventures, Axxam, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven.